Market Cap: $18.87M
KI
Karyopharm Therapeutics Inc.
KPTI
NASDAQ (NASDAQ Global Select)USD
Market Cap: $18.87M
Karyopharm Therapeutics Inc. (Ticker: KPTI) is making significant strides in the field of oncology with its innovative approach to treating myelofibrosis. The company recently announced that its late-…
Karyopharm Therapeutics (Ticker: KPTI) gears up for a significant presentation at the upcoming ASCO conference, where it will unveil detailed results from its pivotal Phase 3 SENTRY trial. This trial…
Karyopharm Therapeutics Inc (Ticker: KPTI) engages in pioneering innovative cancer therapies, showcasing its commitment through participation in key industry events such as the upcoming investor confe…
Karyopharm's Strategic Fundraising Effort to Propel Clinical Development Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announces a significant securities purchase agreement with RA Capital Management, a…
Karyopharm Expands Talent Pool with New Stock Incentives Karyopharm Therapeutics Inc., a leading pharmaceutical company specializing in innovative cancer therapies, announces a significant move to enh…
Karyopharm Therapeutics Strengthens Talent Pool with New Stock Incentives Karyopharm Therapeutics Inc. solidifies its commitment to innovative cancer therapies by announcing the grant of 1,450 restric…
Karyopharm Expands Talent Pool to Drive Innovative Cancer Treatments Karyopharm Therapeutics Inc., a commercial-stage biopharmaceutical company known for its cutting-edge cancer therapies, reinforces…
Karyopharm Therapeutics Enhances Talent Pool with New Inducement Grants Karyopharm Therapeutics Inc., a prominent player in the field of cancer therapeutics, announces the recent granting of 1,533 res…
Karyopharm Therapeutics Expands Workforce with Strategic Inducement Grants Karyopharm Therapeutics Inc., a company dedicated to innovative cancer therapies, announces the granting of 1,533 restricted…
Karyopharm Therapeutics Enhances Focus on Myelofibrosis in Upcoming Event Karyopharm Therapeutics Inc., a Massachusetts-based pharmaceutical company specializing in innovative cancer therapies, prepar…
Karyopharm Therapeutics Advances Cancer Treatment with Innovative Oral Therapies Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company based in Newton, Massachusetts, continues to ma…
Karyopharm Therapeutics Enhances Focus on Myelofibrosis Treatments Amid Industry Developments Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical firm based in Newton, Massachusetts, is so…
Karyopharm Therapeutics Advances Cancer Treatment at Upcoming Healthcare Conference Karyopharm Therapeutics Inc., a notable player in the pharmaceutical industry, is set to showcase its groundbreaking…
Karyopharm Therapeutics Advances Cancer Treatment Strategies Karyopharm Therapeutics Inc., an innovative player in the oncology pharmaceutical sector, continues to solidify its reputation through its…
Karyopharm's Innovative Approach to Cancer Treatment at Healthcare Conference Karyopharm Therapeutics Inc., a prominent player in the pharmaceutical industry, focuses on innovative cancer therapies th…
Karyopharm Therapeutics Strengthens Workforce with New Inducement Grants On November 3, 2025, Karyopharm Therapeutics Inc. announced the grant of 800 restricted stock units (RSUs) to a newly hired emp…
Karyopharm Therapeutics Strengthens Workforce with Stock Incentives Karyopharm Therapeutics Inc. continues to bolster its commitment to talent acquisition and retention by granting 800 restricted stoc…
Karyopharm Therapeutics Gears Up for Key Earnings Report Amid Competitive Biotech Landscape Karyopharm Therapeutics, a notable player in the biotechnology sector known for its innovative treatments ta…
Karyopharm Therapeutics Poised for Key Earnings Report Amid Strategic Developments Karyopharm Therapeutics Inc., a prominent player in the oncology pharmaceutical landscape, is set to release its quar…
Karyopharm Therapeutics Strengthens Financial Position with Strategic Financing Initiative Karyopharm Therapeutics Inc. announces a significant strategic financing initiative, aiming to secure approxi…
Karyopharm Therapeutics Secures $100 Million Financing to Enhance R&D Efforts Karyopharm Therapeutics Inc. recently announces a pivotal financing initiative that aims to bolster its financial position…
Karyopharm Therapeutics Strengthens Financial Foundation with $100 Million Financing Initiative Karyopharm Therapeutics Inc. is currently enhancing its financial position through a comprehensive serie…
Karyopharm Therapeutics Strengthens Workforce with New Stock Incentives Karyopharm Therapeutics Inc., a notable player in the oncology sector, emphasizes its commitment to innovation and employee rete…
Karyopharm Therapeutics Expands Workforce to Enhance Cancer Treatment Innovations Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company focused on innovative oncology therapies, stre…
Karyopharm Therapeutics Strengthens Talent Base with New Hire and Stock Incentive Karyopharm Therapeutics Inc., a prominent player in the oncology pharmaceutical sector, announces a strategic move to…